NORCROSS, Ga., June 4 /PRNewswire-FirstCall/ -- Immucor, Inc. (Nasdaq:
BLUD), a global leader in providing automated instrument-reagent systems to
the blood transfusion industry, today announced revenue and earnings
guidance for the fiscal year ending May 31, 2009.
For fiscal year 2009:
-- The company expects revenues to range from $292 million to
-- Gross margin is expected to be in the range of 70% to 71%.
-- Net income is expected to be in the range of $80.0 million to
-- We expect to generate earnings per diluted share in the range of
$1.11 to $1.15.
We base our projections on our history of operations, the recurring
nature of a significant portion of our revenues, including contractually
committed purchases from large customers, and the predictability of our
expenses through the fiscal year.
In making this projection, management has made the following assumptions:
-- With respect to revenues, the Company has extrapolated recent past
results and assumed the Company will generate additional revenues from
the implementation of our price strategy, the continuing sales of the
Galileo(R) and Echo(R) instruments in North America, Japan and Europe
and the reagent growth associated with these instrument placements.
-- With respect to the pending BioArray acquisition, the Company has
excluded the impact of the acquisition from these projections. As
previously announced the Company expects dilution of approximately
$0.20 to $0.23 in EPS in the first full year of operations following
closing, including approximately $0.05 per share of dilution resulting
from non-cash amortization expense.
-- With respect to stock based compensation expense, the Company expects
an increase of approximately $1.0 million.
Immucor, Inc. will host a confe
|SOURCE Immucor, Inc.|
Copyright©2008 PR Newswire.
All rights reserved